TY 1091
Alternative Names: TY-1091Latest Information Update: 27 Nov 2023
Price :
$50 *
At a glance
- Originator TYK Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 14 Apr 2023 US FDA approves IND application for TY 1091 in Solid tumours prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Apr 2023 TYK Medicines plans a phase I trial for Solid tumour in USA (PO)